SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Please provide your email address to receive an email when new articles are posted on . The benefit of TAVR vs. clinical surveillance for patients with asymptomatic severe aortic stenosis did not vary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results